Allegra-D 24 Hour (Fexofenadine HCl 180 and Pseudoephendrine HCl 240) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 24, 2012

Allegra-D 24 Hour

Allergy Treatment Begins At Home »

Introduction

Avoidance is always the best treatment for allergies regardless of which allergens are the triggers. Interestingly enough, the most effective, least expensive, and simplest options are not always followed. Many people choose medications or vaccinations instead, despite their drawbacks. Fortunately, there are lots of simple methods, both old and new, to help with avoidance. Remember, putting into practice any of these measures can only be helpful in managing your allergies.

The good news is that you really don't have to strip your house down to the bare bones to make it allergy proof. Thorough and regular cleaning generally makes a huge difference in keeping your house as mold and dust free as possible. Patients with asthma or allergic rhinitis that are due to dust mites, molds, or other indoor allergens can feel better by taking these simple measures:

Keep the home cool (between 68 and 72 degrees F);

Read the Allergy Treatment Begins At Home article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Allegra-D 24 Hour User Reviews >>

Allegra-D 24 Hour

10 Common Allergy Triggers Slideshow Pictures

Take the Quiz on Allergies

Nasal Allergy Relief Slideshow Pictures

font size

OVERDOSE

Most reports of fexofenadine hydrochloride overdose contain limited information. However, dizziness, drowsiness, and dry mouth have been reported. For the pseudoephedrine hydrochloride component of ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) , information on acute overdose is limited to the marketing history of pseudoephedrine hydrochloride. Single doses of fexofenadine hydrochloride up to 800 mg (6 healthy volunteers at this dose level), and doses up to 690 mg twice daily for one month (3 healthy volunteers at this dose level), were administered without the development of clinically significant adverse events.

In large doses, sympathomimetics may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscular weakness and tenseness, anxiety, restlessness, and insomnia. Many patients can present a toxic psychosis with delusions and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsions, coma, and respiratory failure.

In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Following administration of terfenadine, hemodialysis did not effectively remove fexofenadine, the major active metabolite of terfenadine, from blood (up to 1.7% removed). The effect of hemodialysis on the removal of pseudoephedrine is unknown.

No deaths occurred in mature mice and rats at oral doses of fexofenadine hydrochloride up to 5000 mg/kg (approximately 110 and 230 times, respectively, the maximum recommended human daily oral dose of ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) on a mg/m² basis.) The median oral lethal dose in newborn rats was 438 mg/kg (approximately 20 times the maximum recommended human daily oral dose of ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) on a mg/m² basis). In dogs, no evidence of toxicity was observed at oral doses up to 2000 mg/kg (approximately 300 times the maximum recommended human daily oral dose of ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) on a mg/m² basis). The oral median lethal dose of pseudoephedrine hydrochloride in rats was 1674 mg/kg (approximately 55 times the maximum recommended human daily oral dose of ALLEGRA-D 24 HOUR on a mg/m² basis).

CONTRAINDICATIONS

ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) is contraindicated in patients with known hypersensitivity to any of its ingredients.

Due to its pseudoephedrine component, ALLEGRA-D 24 HOUR (fexofenadine hcl 180 and pseudoephendrine hcl 240) is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment (see DRUG INTERACTIONS section). It is also contraindicated in patients with severe hypertension, or severe coronary artery disease, and in those who have shown idiosyncrasy to its components, to adrenergic agents, or to other drugs of similar chemical structures. Manifestations of patient idiosyncrasy to adrenergic agents include: insomnia, dizziness, weakness, tremor, or arrhythmias.

Last reviewed on RxList: 5/10/2010
This monograph has been modified to include the generic and brand name in many instances.